Company Filing History:
4 out of 263 
3 out of 51 
1 out of 24 
Years Active: 2021-2025
Title: Owen Alexander Davis: Innovator in Cancer Research
Introduction
Owen Alexander Davis is a prominent inventor based in London, GB. He has made significant contributions to the field of cancer research, holding a total of 4 patents. His work focuses on developing inhibitors that target B-cell lymphoma 6 (BCL6), a critical factor in various proliferative disorders.
Latest Patents
Davis's latest patents include innovative compounds designed to inhibit BCL6 activity. The first patent, titled "Benzimidazolone derived inhibitors of BCL6," describes compounds of Formula I that serve as inhibitors of BCL6 activity. These compounds are essential in the treatment of proliferative disorders, including cancer. The second patent, simply referred to as "BCL6 inhibitors," also details compounds of Formula I with similar functions and applications. Both patents emphasize the processes for preparing these compounds and their pharmaceutical compositions.
Career Highlights
Throughout his career, Owen Alexander Davis has worked with notable organizations such as Cancer Research Technology Limited and the Institute of Cancer Research: Royal Cancer Hospital. His work in these institutions has been pivotal in advancing cancer treatment methodologies.
Collaborations
Davis has collaborated with esteemed colleagues, including Benjamin Richard Bellenie and Kwai Ming Jack Cheung. These partnerships have further enriched his research and development efforts in the field of cancer therapeutics.
Conclusion
Owen Alexander Davis stands out as an influential inventor in cancer research, with a focus on BCL6 inhibitors. His contributions through patents and collaborations continue to impact the fight against cancer and related diseases.